• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Testing participation in BRCA1/2-positive families: initiator role of index cases.

作者信息

Blandy Cécile, Chabal Françoise, Stoppa-Lyonnet Dominique, Julian-Reynier Claire

机构信息

Service de Génétique, Institut Curie, 26 rue d'Ulm, F75248 Paris cedex 5, France.

出版信息

Genet Test. 2003 Fall;7(3):225-33. doi: 10.1089/109065703322537241.

DOI:10.1089/109065703322537241
PMID:14658447
Abstract

The objectives of this study were to: (1) describe diffusion of information by affected women in whom a mutation has been identified (index cases) to their families and testing participation among high-risk relatives; (2) assess information recall and understanding by index cases and their satisfaction with the testing process; and (3) determine the factors associated with higher/lower testing decision in the family. Thirty index cases completed a self-administered questionnaire assessing their personal and family characteristics and their satisfaction with their own genetic testing process and a telephone interview to evaluate their knowledge about the risk of a genetic predisposition to breast and ovarian cancer, the type and number of close relatives that they informed, and the difficulties that they encountered. Information about breast/ovarian cancer risk and test availability was generally well transmitted (75%), predominantly (88%) to first-degree relatives. In contrast, testing participation was low (15%) and essentially occurred among sisters and daughters. There was a general lack of knowledge despite a high level of satisfaction regarding the information given by the geneticist. Family support and the knowledge of index cases about the risk of transmission of BRCA1/2 mutations by women were found to be positively and significantly associated with the testing decision among first-degree relatives. Difficulties in informing relatives appeared to be related to poor understanding of the information by index cases, as well as fear, and avoidance among close relatives. A major challenge for genetic counseling is to ensure that consulting patients not only receive complete understanding but also understand this information and anticipate the impact of the test result before deciding to take the test.

摘要

相似文献

1
Testing participation in BRCA1/2-positive families: initiator role of index cases.
Genet Test. 2003 Fall;7(3):225-33. doi: 10.1089/109065703322537241.
2
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.遗传性乳腺癌-卵巢癌家族中的BRCA1检测。一项关于患者决策及结果的前瞻性研究。
JAMA. 1996 Jun 26;275(24):1885-92.
3
Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.有遗传性乳腺癌/卵巢癌基因突变携带风险的男性:基因检测期间的态度和心理功能探索
Eur J Hum Genet. 2001 Jul;9(7):492-500. doi: 10.1038/sj.ejhg.5200668.
4
Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.考虑进行BRCA1和BRCA2检测的乳腺癌和/或卵巢癌女性及其配偶的态度、知识、风险认知和决策
Psychooncology. 2003 Jul-Aug;12(5):410-27. doi: 10.1002/pon.653.
5
Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.以色列遗传性乳腺癌/卵巢癌的遗传咨询:心理社会影响及遗传信息留存情况
Am J Med Genet. 2002 Aug 1;111(2):147-51. doi: 10.1002/ajmg.10550.
6
An exploration of the communication preferences regarding genetic testing in individuals from families with identified breast/ovarian cancer mutations.探讨具有明确乳腺癌/卵巢癌基因突变家族成员对基因检测的沟通偏好。
Fam Cancer. 2011 Mar;10(1):97-105. doi: 10.1007/s10689-010-9383-0.
7
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.携带BRCA1和BRCA2突变的阿什肯纳兹犹太女性患卵巢癌的风险。
Clin Cancer Res. 2002 Dec;8(12):3776-81.
8
Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.BRCA1和BRCA2基因突变检测结果呈阳性后的心理社会问题:焦点小组和需求评估调查的结果
CMAJ. 2001 Apr 3;164(7):1005-9.
9
Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas.巴哈马将BRCA突变携带者亲属纳入基因检测项目的策略。
Clin Genet. 2015 Aug;88(2):182-6. doi: 10.1111/cge.12468. Epub 2014 Sep 6.
10
Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.患有乳腺癌和/或卵巢癌的土耳其女性及其亲属中的新型种系BRCA1和BRCA2突变
Cancer Invest. 2006 Aug-Sep;24(5):484-91. doi: 10.1080/07357900600814706.

引用本文的文献

1
Association between proband characteristics and CDH1 cascade genetic testing uptake in at-risk relatives.先证者特征与高危亲属中CDH1级联基因检测接受情况之间的关联。
J Genet Couns. 2025 Jun;34(3):e70011. doi: 10.1002/jgc4.70011.
2
Expanding access to genetic testing for pancreatic cancer.扩大胰腺癌基因检测的可及性。
Fam Cancer. 2024 Aug;23(3):247-254. doi: 10.1007/s10689-024-00389-w. Epub 2024 May 11.
3
Cascade genetic testing for hereditary cancer syndromes: a review of barriers and breakthroughs.级联遗传检测在遗传性癌症综合征中的应用:障碍与突破的综述。
Fam Cancer. 2024 Jun;23(2):111-120. doi: 10.1007/s10689-024-00373-4. Epub 2024 Mar 26.
4
Do people with hereditary cancer syndromes inform their at-risk relatives? A systematic review and meta-analysis.患有遗传性癌症综合征的人会告知他们有患病风险的亲属吗?一项系统评价和荟萃分析。
PEC Innov. 2023 Feb 17;2:100138. doi: 10.1016/j.pecinn.2023.100138. eCollection 2023 Dec.
5
Cancer Genetic Services in a Low- to Middle-Income Country: Cross-Sectional Survey Assessing Willingness to Undergo and Pay for Germline Genetic Testing.中低收入国家的癌症遗传服务:横断面调查评估对种系遗传检测的接受意愿和支付意愿。
JCO Glob Oncol. 2023 Feb;9:e2100140. doi: 10.1200/GO.21.00140.
6
What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing.长期来看:通过级联检测发现致病性变异的高危亲属中癌症监测和预防策略的采用情况。
Cancer. 2022 Dec 15;128(24):4241-4250. doi: 10.1002/cncr.34482. Epub 2022 Oct 27.
7
Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?级联遗传检测完成障碍:我们如何提高遗传性乳腺癌和卵巢癌综合征检测的采用率?
Fam Cancer. 2023 Apr;22(2):127-133. doi: 10.1007/s10689-022-00316-x. Epub 2022 Oct 8.
8
Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.遗传性癌症综合征的级联检测:我们是否应该转向直系亲属接触?系统评价和荟萃分析。
J Clin Oncol. 2022 Dec 10;40(35):4129-4143. doi: 10.1200/JCO.22.00303. Epub 2022 Aug 12.
9
Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention.妇科癌症风险与遗传学:为妇科癌症预防建立理想模型。
Curr Oncol. 2022 Jun 30;29(7):4632-4646. doi: 10.3390/curroncol29070368.
10
Sharing genetic test results with family members of BRCA, PALB2, CHEK2, and ATM carriers.与 BRCA、PALB2、CHEK2 和 ATM 携带者的家庭成员共享基因检测结果。
Patient Educ Couns. 2021 Apr;104(4):720-725. doi: 10.1016/j.pec.2020.12.019. Epub 2021 Jan 5.